|
" Antibodies : "
edited by G. Subramanian.
| Document Type
|
:
|
BL
|
| Record Number
|
:
|
739208
|
| Doc. No
|
:
|
b559128
|
| Main Entry
|
:
|
edited by G. Subramanian.
|
| Title & Author
|
:
|
Antibodies : : Volume 2: Novel Technologies and Therapeutic Use\ edited by G. Subramanian.
|
| Publication Statement
|
:
|
Boston, MA: Springer US, 2004
|
| Page. NO
|
:
|
(xvi, 232 pages)
|
| ISBN
|
:
|
1441988777
|
|
|
:
|
: 9781441988775
|
| Contents
|
:
|
1. Transgenic technology for monoclonal antibody production --;2. Generation, engineering and production of human antibodies using HuCAL --;3. Achieving appropriate glycosylation during the scaleup of antibody production --;4. Approaches to devise antibody purification processes by chromatography --;5. Novel HIV neutralizing antibodies selected from phage display libraries --;6. Monoclonal and bispecific antibodies in combination with radiotherapy for cancer treatment --;7. Antibodies, a potent tool to target genes into designated cells and tissues --;8. Intrabodies: development and application in functional genomics and therapy --;9. Expression of recombinant antibodies by tumour cells: on road to anti-tumour therapy --;10. Antitumor antibodies: from research to clinic --;11. Macrophages for immunotherapy --;12. Future prospects in antibody engineering and therapy --;Index.
|
| Abstract
|
:
|
Both the nature of monoclonal antibody therapies and the relatively large size of the monoclonal antibody dictate the production requirements, for many ofthese therapeutics the monoclonal antibody product will be 100 kilogrammes or more per year.
|
| Subject
|
:
|
Immunology.
|
| Subject
|
:
|
Pharmacy.
|
| Subject
|
:
|
Toxicology.
|
| Added Entry
|
:
|
G Subramanian
|
| |